Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

QNRX vs REVB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REVB Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 4–3 Matrix Metrics)

REVB Overall Winner 6-Pillar Tally: QNRX 1 – 3 REVB (2 Tie) Matrix Metrics: QNRX 3 – 4 REVB

As of Nov 19, 2026, Revelation Biosciences, Inc. (REVB) is the stronger overall head-to-head candidate over Quoin Pharmaceuticals, Ltd. (QNRX) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). QNRX carries a Unified Composite Score of 47.1/100 (HOLD) at $3.36 (N/M Forward P/E, 0.0% operating margin), whereas REVB carries 43.7/100 (HOLD) at $3.69 (0.9x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While QNRX currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. REVB 43.7/100 HOLD), REVB captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: QNRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.8); meanwhile REVB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About QNRX vs REVB
QNRX NASDAQ
Quoin Pharmaceuticals, Ltd. American Depositary Shares
Pharmaceutical Preparations
$3.36
-5.64% 1D
Market Cap $17.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.35β · 72% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.2%), weak momentum, RSI 34
RSI-14: 33.8 · SMA20: $3.85 · SMA50: $4.71
REVB NASDAQ Head-to-Head Winner
Revelation Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$3.69
-4.16% 1D
Market Cap $2.1M
TTM Revenue N/A
Forward P/E 0.9x
Beta / 30D Vol 2.90β · 101% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 38.0 Fund 24.0 Flow 50.0 Mom 36.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (107.4% over 20 days), RSI 56
RSI-14: 55.7 · SMA20: $3.94 · SMA50: $2.24

6-Pillar Scorecard Institutional Category Breakdown (QNRX 1 – 3 REVB)

Columns: Metric · QNRX · REVB
1. Valuation Multiples REVB
Forward P/E N/M 0.9x
Trailing P/E 8.1x 0.9x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale QNRX
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $17.1M $2.1M
3. Profitability & Quality REVB
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -142.6% -133.4%
4. Balance Sheet & Cash Flow REVB
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $5.97 Book/Sh · -142.6% ROE $10.58 Book/Sh · -133.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: QNRX (3) vs REVB (4)
Institutional Metric QNRX REVB Criterion Row Edge
Market Capitalization
Scale
$17.1M $2.1M Larger Scale QNRX
Trailing P/E Ratio
Valuation
8.1x 0.9x Lower Multiple REVB
Forward P/E Ratio
Valuation
N/M 0.9x Lower Multiple REVB
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-142.6% -133.4% Higher ROE REVB
52-Week Range Position
Momentum
0% ($3–$24) 75% ($0–$5) Stronger Trend REVB
Beta / 30D Volatility
Risk Regime
1.35β · 72% Vol 2.90β · 101% Vol Lower Realized Risk QNRX
Unified Institutional Score
Composite Signal
47.1 / 100 (HOLD) 43.7 / 100 (HOLD) Higher Composite QNRX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($5.97 Book/Sh · -142.6% ROE) N/A ($10.58 Book/Sh · -133.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REVB +18.31 pp
QNRX: -15.81% · REVB: +2.5%
3M Horizon REVB +278.22 pp
QNRX: -39.69% · REVB: +238.53%
6M Horizon REVB +272.41 pp
QNRX: -30.74% · REVB: +241.67%
1Y Horizon REVB +411.61 pp
QNRX: -82.54% · REVB: +329.07%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QNRX vs REVB. Trailing 12-month operating profitability (QNRX 0.0% vs REVB 0.0%) and valuation multiples (QNRX N/M vs REVB 0.9x Forward P/E) are benchmarked directly in Pillar 4 below.

QNRX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-142.6% · N/M
REVB ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-133.4% · 0.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
QNRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact QNRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
REVB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact REVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
QNRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $17.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
REVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ QNRX vs REVB Key Questions & Quantitative Answers

As of Nov 19, 2026, Revelation Biosciences, Inc. (REVB) is the stronger overall head-to-head candidate over Quoin Pharmaceuticals, Ltd. (QNRX) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). QNRX carries a Unified Composite Score of 47.1/100 (HOLD) at $3.36 (N/M Forward P/E, 0.0% operating margin), whereas REVB carries 43.7/100 (HOLD) at $3.69 (0.9x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While QNRX currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. REVB 43.7/100 HOLD), REVB captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: QNRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.8); meanwhile REVB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

QNRX leads the Growth & Scale pillar: QNRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with REVB at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, QNRX generates N/A in USD-normalized revenue versus N/A for REVB. In operating R&D and SG&A reinvestment, QNRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for REVB.

REVB screens cheaper on headline valuation multiples. QNRX trades at N/M Forward P/E, 8.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas REVB trades at 0.9x Forward P/E, 0.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against QNRX (-142.6% ROE) versus REVB (-133.4% ROE) capital efficiency.

In options market volatility and institutional positioning, QNRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 72% Vol realized risk). By comparison, REVB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.90β · 101% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.